The Prognostic Significance of Synchronous Metastasis in Glioblastoma Multiforme Patients: a Propensity Score-matched Analysis Using SEER Data

Overview

Journal Front Neurol

Specialty Neurology

Date 2024 Oct 23

PMID 39440248

Authors

Hui Shen

Qing Mei

Xubin Chai

Yuanfeng Jiang

Aihua Liu

Jiachun Liu

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma multiforme (GBM) with synchronous metastasis(SM) is a rare occurrence. We extracted the data of GBM patients from the SEER database to look into the incidence of SM in GBM, determine the prognostic significance of SM in GBM, and assess therapeutic options for patients presenting with SM.

Methods: From 2004 to 2015, information on GBM patients was obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The propensity score matching (PSM) method was employed to mitigate confounding factors between SM and non-SM groups, subsequently investigating the prognostic significance of SM in patients with GBM. Multivariate Cox proportional hazards regression analyses were employed to identify independent prognostic variables for GBM patients with SM. A forest plot was used to visualize the results.

Results: A cohort of 19,708 patients was obtained from the database, among which 272 (1.4%) had SM at the time of diagnosis. Following PSM at a 3:1 ratio, in both univariate and multivariate cox regression analysis, SM (HR = 1.27, 95% CI: 1.09-1.46) was found to be an independent predictive predictor for GBM patients. Furthermore, the Cox proportional hazard forest plot demonstrated that independent risk variables for GBM patients with SM included age (Old vs. Young, HR = 1.44, 95% CI: 1.11-1.88), surgery (biopsy vs. no surgery, HR = 0.67, 95% CI: 0.46-0.96;Subtotal resection vs. no surgery, HR = 0.47, 95% CI: 0.32-0.68;Gross total resection vs. no surgery, HR = 0.44, 95% CI: 0.31-0.62), radiotherapy (HR = 0.58, 95% CI: 0.41-0.83), and chemotherapy (HR = 0.51, 95% CI: 0.36-0.72).

Conclusion: The predictive value of SM in GBM was determined by this propensity-matched analysis using data from the SEER database. Radiotherapy, chemotherapy, and surgery constitute an effective treatment regimen for patients with SM. A more positive approach toward the use of aggressive treatment for GBM patients with SM may be warranted.

References

Shibahara I, Saito R, Osada Y, Kanamori M, Sonoda Y, Kumabe T . Incidence of initial spinal metastasis in glioblastoma patients and the importance of spinal screening using MRI. J Neurooncol. 2018; 141(2):337-345. DOI: 10.1007/s11060-018-03036-4. View

Ostrom Q, Price M, Neff C, Cioffi G, Waite K, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2023; 25(12 Suppl 2):iv1-iv99. PMC: 10550277. DOI: 10.1093/neuonc/noad149. View

Lombard A, Goffart N, Rogister B . Glioblastoma Circulating Cells: Reality, Trap or Illusion?. Stem Cells Int. 2015; 2015:182985. PMC: 4452868. DOI: 10.1155/2015/182985. View

Witoonpanich P, Bamrungrak K, Jinawath A, Wongwaisayawan S, Phudhichareonrat S, Witoonpanich R . Glioblastoma multiforme at the corpus callosum with spinal leptomeningeal metastasis. Clin Neurol Neurosurg. 2011; 113(5):407-10. DOI: 10.1016/j.clineuro.2010.12.001. View

Georgescu M, Olar A . Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma. Acta Neuropathol Commun. 2020; 8(1):10. PMC: 6998196. DOI: 10.1186/s40478-020-0889-x. View

Dardis C, Milton K, Ashby L, Shapiro W . Leptomeningeal metastases in high-grade adult glioma: development, diagnosis, management, and outcomes in a series of 34 patients. Front Neurol. 2014; 5:220. PMC: 4217477. DOI: 10.3389/fneur.2014.00220. View

Yang R, Isaacs A, Cadieux M, Hirmer T, CreveCoeur T, Lapointe A . Primary and metastatic glioblastoma of the spine in the pediatric population: a systematic review. Childs Nerv Syst. 2021; 37(6):1849-1858. DOI: 10.1007/s00381-021-05098-8. View

Amelot A, Terrier L, Cognacq G, Jecko V, Marlier B, Seizeur R . Natural history of spinal cord metastasis from brain glioblastomas. J Neurooncol. 2023; 162(2):373-382. DOI: 10.1007/s11060-023-04298-3. View

Senhaji N, Squalli Houssaini A, Lamrabet S, Louati S, Bennis S . Molecular and Circulating Biomarkers in Patients with Glioblastoma. Int J Mol Sci. 2022; 23(13). PMC: 9267689. DOI: 10.3390/ijms23137474. View

10.

Wright C, Wright J, Onyewadume L, Raghavan A, Lapite I, Casco-Zuleta A . Diagnosis, treatment, and survival in spinal dissemination of primary intracranial glioblastoma: systematic literature review. J Neurosurg Spine. 2019; 31(5):723-732. DOI: 10.3171/2019.5.SPINE19164. View

11.

Chistiakov D, Chekhonin V . Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Exp Mol Pathol. 2018; 105(2):166-174. DOI: 10.1016/j.yexmp.2018.07.007. View

12.

Lun M, Lok E, Gautam S, Wu E, Wong E . The natural history of extracranial metastasis from glioblastoma multiforme. J Neurooncol. 2011; 105(2):261-73. DOI: 10.1007/s11060-011-0575-8. View

13.

Zhang K, Yang Y, Zhuang J, Guo G, Chao X, Zhang Z . Intracranial dissemination of glioblastoma multiforme: a case report and literature review. J Int Med Res. 2022; 50(7):3000605221112047. PMC: 9310070. DOI: 10.1177/03000605221112047. View

14.

Bark J, Kulasinghe A, Chua B, Day B, Punyadeera C . Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2019; 122(3):295-305. PMC: 7000822. DOI: 10.1038/s41416-019-0603-6. View

15.

McKinnon C, Nandhabalan M, Murray S, Plaha P . Glioblastoma: clinical presentation, diagnosis, and management. BMJ. 2021; 374:n1560. DOI: 10.1136/bmj.n1560. View

16.

Pietschmann S, von Bueren A, Kerber M, Baumert B, Kortmann R, Muller K . An individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central nervous system. PLoS One. 2015; 10(4):e0121592. PMC: 4393116. DOI: 10.1371/journal.pone.0121592. View

17.

Smith D, Hardman J, EARLE K . Metastasizing neuroectodermal tumors of the central nervous system. J Neurosurg. 1969; 31(1):50-8. DOI: 10.3171/jns.1969.31.1.0050. View

18.

Ray A, Manjila S, Hdeib A, Radhakrishnan A, Nock C, Cohen M . Extracranial metastasis of gliobastoma: Three illustrative cases and current review of the molecular pathology and management strategies. Mol Clin Oncol. 2015; 3(3):479-486. PMC: 4471516. DOI: 10.3892/mco.2015.494. View

19.

Wen P, Weller M, Quant Lee E, Alexander B, Barnholtz-Sloan J, Barthel F . Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020; 22(8):1073-1113. PMC: 7594557. DOI: 10.1093/neuonc/noaa106. View

20.

Choi P, Shapera S . What's your call? Drop metastases. CMAJ. 2006; 175(5):475, 477. PMC: 1550743. DOI: 10.1503/cmaj.060308. View